Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092001 · ClinicalTrials.gov registry record · Phase 2
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 14
- Study locations
NCT00092001: Completed Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
NCT00092001 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 111 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (66% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00092001, a Phase 2 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
Conditions Studied
Interventions
- DRUG Sunitinib
Study Locations (14)
North Carolina
- Pfizer Investigational Site - Chapel Hill
- Pfizer Investigational Site - Clinton
- Pfizer Investigational Site - Goldsboro
- Pfizer Investigational Site - Pollocksville
- Pfizer Investigational Site - Wilson
Missouri
- Pfizer Investigational Site - City of Saint Peters
- Pfizer Investigational Site - St Louis
- Pfizer Investigational Site - St Louis
Maryland
- Pfizer Investigational Site - Baltimore
Pennsylvania
- Pfizer Investigational Site - Pittsburgh
Virginia
- Pfizer Investigational Site - Charlottesville
Other
- Pfizer Investigational Site - Orbassano (Torino)
Barcelona
- Pfizer Investigational Site - Badalona
BARCELONA
- Pfizer Investigational Site - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00092001 record still lists
NCT00092001 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Sunitinib is the first listed.
NCT00092001 lists 14 locations in 8 states (North Carolina, Missouri, Maryland).
Frequently Asked Questions
What is clinical trial NCT00092001 about?
NCT00092001 is a clinical study titled "Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
What is the current status of trial NCT00092001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2005-01. Estimated completion is 2007-03.
What conditions does trial NCT00092001 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00092001?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00092001?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00092001 being conducted?
This trial has 14 study locations across Maryland, Missouri, North Carolina, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00092001's enrollment target sits among peer trials
111 70th of 130 higher than 61 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia